Strata Critical Medical, Inc. (SRTA)
NASDAQ:SRTA
Want to see SRTA full AI Analyst Report?
Top Page
Strata Critical Medical
(NASDAQ:SRTA)
Select Model
Select Model
Rating:62Neutral
Price Target:
$6.50
▲(42.23% Upside)
Action:Reiterated
Date:05/09/26
The score is driven primarily by mixed financial quality (strong balance sheet but weak cash-flow history) and constructive technical momentum. Earnings-call commentary and reiterated guidance support the outlook, while a high P/E and lack of dividend yield temper the overall rating.
Positive Factors
Balance Sheet Strength
Very low leverage and substantial equity provide durable financial flexibility: supports aircraft purchases, hub expansion and M&A, reduces refinancing and liquidity risk, and cushions operating volatility. This downside protection is a multi-quarter tailwind for execution and strategic optionality.
Negative Factors
Persistent Cash Burn
Material and persistent negative operating and free cash flow increases reliance on balance sheet liquidity and potential external financing. Over several quarters this undermines earnings quality, constrains reinvestment flexibility, and raises risk if growth or margin improvement stalls.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
Very low leverage and substantial equity provide durable financial flexibility: supports aircraft purchases, hub expansion and M&A, reduces refinancing and liquidity risk, and cushions operating volatility. This downside protection is a multi-quarter tailwind for execution and strategic optionality.
Read all positive factors
Strata Critical Medical (SRTA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$545.98M
Dividend YieldN/A
Average Volume (3M)980.90K
Price to Earnings (P/E)10.3
Beta (1Y)2.06
Revenue Growth1.11%
EPS Growth65.80%
CountryUS
Employees310
SectorHealthcare
Sector Strength45
IndustryAirlines, Airports & Air Services
Share Statistics
EPS (TTM)-0.16
Shares Outstanding86,526,570
10 Day Avg. Volume1,050,472
30 Day Avg. Volume980,896
Financial Highlights & Ratios
PEG Ratio0.55
Price to Book (P/B)1.42
Price to Sales (P/S)2.01
P/FCF Ratio-6.62
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue1.93
Enterprise Value/Gross Profit9.42
Enterprise Value/Ebitda-87.98
Forecast
1Y Price Target
$9.17Price Target Upside100.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.07
Revenue Forecast (FY)$271.35M
Strata Critical Medical Business Overview & Revenue Model
Company Description
Strata Critical Medical, Inc. provides time critical logistics solutions and specialized medical services to healthcare providers across the United States. The company operates as both an air and ground transporter of human organs for transplant. ...
How the Company Makes Money
null...
Strata Critical Medical Earnings Call Summary
Earnings Call Date:May 06, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 11, 2026
Earnings Call Sentiment Positive
The call conveyed a broadly positive tone driven by very strong year-over-year revenue (+87.4%), doubled gross profit, rapid build-out and commercial traction in the Clinical business, healthy cash on hand and an active M&A pipeline. Offsetting these positives were sequential softness in Logistics revenue and margins (customer mix and weather-related disruptions), a sequential decline in adjusted EBITDA margin, some one-time cash timing effects, and ongoing uncertainty in donor volumes. Management reiterated full-year guidance and highlighted balance sheet capacity, suggesting confidence in execution despite near-term noise.Positive Updates
Revenue Growth
Total revenue increased 87.4% year-over-year to $67.4M in Q1 2026 (from $35.9M) and was up ~1% sequentially versus Q4 2025; performance was reported as ahead of guidance for both revenue and adjusted EBITDA.
Negative Updates
Sequential Logistics Softness and Margin Pressure
Logistics revenue fell 3.3% sequentially versus Q4 2025 and Logistics gross margin declined to 19.3% (down 30 bps year-over-year and down 220 bps sequentially), driven by a quarter-to-quarter customer mix shift toward OPOs with shorter trip distances.
Read all updates
Q1-2026 Updates
Positive
Negative
Revenue Growth
Total revenue increased 87.4% year-over-year to $67.4M in Q1 2026 (from $35.9M) and was up ~1% sequentially versus Q4 2025; performance was reported as ahead of guidance for both revenue and adjusted EBITDA.
Read all positive updates
Company Guidance
The company reiterated full-year 2026 guidance of revenue $260–$275M, adjusted EBITDA $29–$33M and free cash flow before aircraft/engine purchases $15–$22M, noting revenue is trending above the midpoint (partly due to higher fuel surcharges) and Logistics gross margins are expected to remain in the ~20% range while Clinical gross margins are trending above expectations (Q1 Clinical GM ~25%); for Q2 they expect revenue to rise low-single-digits sequentially and adjusted EBITDA margin to be ~10%. Q1 2026 metrics: total revenue $67.4M (+87.4% YoY), Logistics revenue $47.6M (+32.4% YoY), Clinical revenue $19.8M (+12.7% sequential), gross profit $14.1M (GM 21.0%), Logistics gross margin 19.3%, Clinical gross margin 25.0%, adjusted EBITDA $6.4M (9.5% margin), adjusted SG&A $9.2M, operating cash flow $3.9M, free cash flow before aircraft acquisitions $2.1M, capex $5.5M (including $3.7M for 1 aircraft). Balance sheet and capital items called out: cash and short-term investments $58.8M, undrawn ABL $30M (potentially upsizable to $50M), expected Joby earn-out ~ $45M (up to $17.5M due in Aug), 14M warrants expiring at $11.50, Ohio Valley acquisition ~ $1M adding ~ $100k adjusted EBITDA for the rest of 2026, 10 owned aircraft (dedicated fleet ~35) and roughly 20 logistics hubs.Strata Critical Medical Financial Statement Overview
Summary
Income Statement
61
Positive
Balance Sheet
82
Very Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 254.27M | 197.14M | 248.69M | 225.18M | 146.12M | 50.53M |
| Gross Profit | 52.18M | 38.33M | 58.92M | 42.12M | 22.27M | 10.52M |
| EBITDA | -5.59M | -2.91M | -27.96M | -61.01M | -69.87M | -23.50M |
| Net Income | 50.78M | -15.65M | -27.31M | -56.08M | -27.26M | -40.05M |
Balance Sheet | ||||||
| Total Assets | 327.62M | 325.47M | 256.68M | 294.94M | 325.02M | 335.88M |
| Cash, Cash Equivalents and Short-Term Investments | 58.79M | 61.23M | 127.14M | 166.14M | 192.08M | 281.97M |
| Total Debt | 4.47M | 3.31M | 9.32M | 24.52M | 18.33M | 716.00K |
| Total Liabilities | 41.89M | 46.40M | 34.74M | 60.64M | 50.54M | 44.51M |
| Stockholders Equity | 285.73M | 279.07M | 221.94M | 234.30M | 274.49M | 291.37M |
Cash Flow | ||||||
| Free Cash Flow | -53.99M | -59.92M | -35.51M | -34.46M | -37.86M | -16.42M |
| Operating Cash Flow | -40.81M | -48.91M | -2.52M | -32.35M | -37.13M | -15.62M |
| Investing Cash Flow | 74.07M | 69.75M | -1.02M | 17.09M | 79.34M | -321.34M |
| Financing Cash Flow | -9.50M | -8.91M | -5.76M | -76.00K | -1.08M | 332.26M |
Strata Critical Medical Technical Analysis
Positive
4.57
Price Trends
4.92
Positive
4.90
Positive
4.84
Positive
Market Momentum
0.38
Negative
63.78
Neutral
85.51
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SRTA, the sentiment is Positive. The current price of 4.57 is below the 20-day moving average (MA) of 5.63, below the 50-day MA of 4.92, and below the 200-day MA of 4.84, indicating a bullish trend. The MACD of 0.38 indicates Negative momentum. The RSI at 63.78 is Neutral, neither overbought nor oversold. The STOCH value of 85.51 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SRTA.
Strata Critical Medical Risk Analysis
Strata Critical Medical disclosed 57 risk factors in its most recent earnings report. Strata Critical Medical reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Strata Critical Medical Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $545.98M | 10.28 | 18.97% | ― | 1.11% | 65.80% | |
54 Neutral | $311.40M | 25.95 | 2.83% | ― | 6.19% | ― | |
54 Neutral | $242.97M | -3.83 | 6.87% | ― | 14.51% | 28.04% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $124.49M | -0.22 | 140.66% | ― | -3.24% | 35.57% |
* Healthcare Sector Average
SRTA
Strata Critical Medical
6.12
2.60
73.86%
ASLE
AerSale Corporation
6.52
0.54
9.03%
FLYX
flyExclusive
2.63
-0.46
-14.89%
SRFM
Surf Air Mobility, Inc.
1.16
-1.36
-53.97%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.